Insights On Drug Development

  1. Flexibility And Scientific Innovation In OSD Development At Our Bend, Oregon Site 8/31/2026

    Watch the video series to see how the right CDMO partner can help anticipate challenges, reduce development risk, and keep your program moving with confidence on the path to market.

  2. Leveraging Early Insights To Accelerate The Oral Drug Development Cycle 8/31/2026

    Consider how the following early development insights can help you navigate complex oral drug development and move your program forward with greater confidence.

  3. How To Achieve Late-Phase Success In Complex OSD Development 8/31/2026

    Late-phase OSD scale-up demands more than technical know-how. This paper examines the frameworks, tools, and partnership models that determine whether promising molecules reach commercial production reliably.

  4. Reducing Uncertainty In Early Oral Drug Development 8/31/2026

    Five recurring decision points in early oral solid dose development carry outsized downstream consequences. AI/ML-driven predictive modeling is reframing how teams manage those decisions under API and timeline constraints.

  5. Lipid Formulation Development: Why Softgels Are The Technology Of Choice 8/31/2026

    Low bioavailability affects roughly 80% of APIs, yet many drug developers default to standard OSD forms. This paper examines why softgels deserve earlier consideration in formulation strategy.

  6. 5 Hidden Risks In Early-Phase OSD Formulation Development 8/31/2026

    Early formulation decisions in OSD development carry risks that may not surface until later stages, when the cost of course correction is significantly higher.

  7. Overview Of Hot Melt Extrusion And Its Pharmaceutical Applications 8/31/2026

    More than 40% of NCEs face aqueous solubility challenges. Here, we examine how hot melt extrusion addresses solubility, modified release, abuse deterrence, and scale-up across pharmaceutical development.

  8. Enabling Flexibility And Scientific Innovation In OSD Development 8/31/2026

    How one clinical-stage CNS biotech navigated early formulation complexity, shifting pipeline priorities, and scalable manufacturing demands through a strategic CDMO partnership.

  9. 3 Decision Domains Shaping Sterile Drug Product Success 8/28/2026

    In sterile development, the decisions with the greatest downstream consequences are rarely recognized as such when they are made. Examine how these choices shape program outcomes across the lifecycle.

  10. How Dosage Form Decisions Shape Pediatric And Geriatric Drug Development 8/27/2026

    Developing pediatric and geriatric pharmaceuticals requires customized strategies beyond tablet crushing, balancing specific age-related palatability, packaging, real-world administration, and lifecycle management needs for optimal patient outcomes.